Table 1.
Patient baseline characteristics
| Characteristics | Value |
| Total enrolled | 80 |
| Age (yr), mean (SD) | 71.3±10.9 |
| Sex | |
| Male | 61 (76%) |
| Female | 19 (24%) |
| Race | |
| White | 53 (66%) |
| Asian | 11 (14%) |
| Black | 10 (13%) |
| Unknown/not reported | 4 (5%) |
| American Indian/Alaska Native | 1 (1%) |
| More than one race/multiracial | 1 (1%) |
| Ethnicity | |
| Non-Hispanic | 77 (96%) |
| Hispanic | 2 (3%) |
| Unknown/not reported | 1 (1%) |
| Cause of CKD | |
| DM type 2 | 63 (79%) |
| Other | 17 (21%) |
| Medical history | |
| CHF | 20 (25%) |
| CAD | 26 (33%) |
| Hypertension | 77 (96%) |
| Stroke | 17 (21%) |
| History of malignancy | 6 (8%) |
| eGFR, n (%) | |
| 0 to ≤15 ml/min | 15 (19%) |
| >15 to ≤30 ml/min | 34 (43%) |
| >30 to ≤45 ml/min | 31 (39%) |
| Years of known kidney disease | 6.8±7.4 |
| Body mass index, n (%) | |
| ≤25 kg/m2 | 14 (18%) |
| >25 to ≤30 kg/m2 | 33 (41%) |
| >30 to ≤35 kg/m2 | 21 (26%) |
| >35 kg/m2 | 12 (15%) |
| Fasting glucose (mg/dl) | 160.2±59.4 |
| HbA1c (%) | 7.2±1.5 |
| Serum fructosamine, µmol/L | 304.1±57.3 |
| Medications | |
| Insulin | |
| Insulin, short acting only | 10 (13%) |
| Insulin, long acting only | 14 (18%) |
| Insulin, short and long acting | 18 (23%) |
| Sulfonylureas | 22 (28%) |
| Insulin and sulfonylureas | 8 (10%) |
| Other oral hypoglycemic agents other than SU and GLP | 27 (34%) |
| GLP-1 receptor agonists | 10 (13%) |
Adapted from Presswala et al. (10). DM, diabetes mellitus; CHF, congestive heart failure; CAD, coronary artery disease; HbA1c, hemoglobin A1c; SU, sulfonylureas; GLP, glucagon-like peptide-1 receptor agonists; GLP-1, glucagon-like peptide 1.